Cresco Labs Inc. (CRLBF)
(Delayed Data from OTC)
$1.62 USD
-0.07 (-4.14%)
Updated Jun 14, 2024 04:00 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Cresco Labs Inc. (CRLBF) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.58 | $14.32 | $2.00 | 171.01% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Cresco Labs Inc. comes to $4.58. The forecasts range from a low of $2.00 to a high of $14.32. The average price target represents an increase of 171.01% from the last closing price of $1.69.
Analyst Price Targets (9 )
Broker Rating
Cresco Labs Inc. currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.45 a month ago based on 11 recommendations.
Of the 10 recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 70% and 10% of all recommendations. A month ago, Strong Buy made up 72.73%, while Buy represented 9.09%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 8 | 8 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.45 | 1.45 | 1.30 | 1.30 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/21/2024 | Cormark Securities | Jesse Pytlak | Moderate Buy | Moderate Buy |
5/16/2024 | Needham & Company | Matthew R Mcginley | Not Available | Hold |
5/15/2024 | Alliance Global Partners | Aaron Grey | Strong Buy | Strong Buy |
3/15/2024 | Wedbush Securities | Gerald Pascarelli | Strong Buy | Strong Buy |
3/13/2024 | ATB Capital Markets | Frederico Gomes | Strong Buy | Strong Buy |
3/13/2024 | Roth Capital Partners | Scott Fortune | Hold | Hold |
3/13/2024 | Echelon Welath Partners | Andrew Semple | Hold | Strong Buy |
2/16/2024 | Haywood Securities | Neal Gilmer | Strong Buy | Strong Buy |
11/16/2023 | Canaccord Genuity | Luke Hannan | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.45 |
# of Recs in ABR | 10 |
Average Target Price | $4.58 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 139 of 252 |
Current Quarter EPS Est: | -0.02 |